Biologics Market Report and Forecast 2025-2034
Description
The global biologics market size was valued at USD 381.90 Billion in 2024, driven by the growing demand for biologics therapeutics to treat chronic diseases across the globe. The market is expected to grow at a CAGR of 7.20% during the forecast period of 2025-2034, with the values likely to rise from USD 416.3 Billion in 2025 to USD 765.42 Billion by 2034.
Global Biologics Market Overview
Biologics include products obtained from living organisms or their certain components. Biologic drugs can be derived from humans, animals, or microorganisms by utilizing biotechnological techniques. It includes a diverse range of therapeutic products such as vaccines, blood components, tissues, genes, and recombinant proteins. Biologics are considered the most advanced therapies, used for treating diseases such as rheumatoid arthritis, and Crohn’s disease, among other autoimmune disorders.
The biologics market demand is driven by the prevalence of chronic diseases, necessitating the need for improved diagnostics and treatment drugs. There is an increased impetus for research and development activities to enhance the productivity of biologics products. Biologics have shown promising results in the treatment of chronic diseases such as rheumatoid arthritis (RA), which poses a lifetime risk of 4% in women and 3% in men. Studies have revealed that biologics can improve joint function in patients with RA, along with reducing drug dependency. Thus, it opens a wide avenue for effective therapeutics, that can fuel the growth of the biologics market.
Rising Investments to Fuel Biologics Market Growth
The increased investment and funding to accelerate the expansion of biologics research and manufacturing facilities is driving the market growth. In October 2023, Syngene International, Biocon's global innovation-focused subsidiary, announced its annual investment plan of USD 100 million in biologics, research, and small molecules. The company also revealed that their biologics division is rapidly expanding and delivering positive results. With the latest investment strategy, the company plans to enhance their manufacturing capabilities along with capacity expansion to align with the rising demand of the biologics market.
Technological Advancements to Develop High-Quality Biologics
Biologics represent cutting-edge medicines with the potential to treat medical conditions with no other treatment available. Biopharmaceutical companies are working towards developing standards and reference materials to improve quality assessment in the biological therapies space, expected to bolster the biologics market share in the forecast period.
In October 2023, American Type Culture Collection (ATCC) and United States Pharmacopeia (USP), two United States-based nonprofit premier global biological materials management and standard organizations, launched a set of 6 products to mitigate the risk involved in the manufacturing of biologics such as vaccines. The joint products marketed by the companies contain pure genomic DNA that can advance quality control of various biotherapeutic products by measuring residual host cell DNA. The development of such reference materials will ensure the quality and safety of biologics and will subsequently help in the market growth.
Strategic Collaborations to Boost Biologics Market Size
To meet the rising demand for biologics, biopharmaceutical companies are entering into strategic collaborations and partnerships to achieve substantial market share. In October 2023, Salipro Biotech AB (a Sweden-based biotechnology company) and Icosagen (a contract research, development, and manufacturing organization headquartered in Estonia) announced their collaboration to accelerate drug discovery programs. The alliance is primarily focused on monoclonal antibody discovery and characterization against challenging membrane proteins. By leveraging the shared resources and expertise, the companies plan to establish a solid foundation for biologic drug development.
Global Biologics Market Segmentation
"Biologics Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Source Human mABs
Humanized mABs
Chimeric mABs
Murine mABs Stem Cell Therapy
CAR-T Cell Therapy
North America is the leading market in the biologics sector, which can be attributed to the rising prevalence of chronic diseases and growing awareness around advanced technologies such as gene therapy and RNAi therapy. In addition, the presence of leading biopharmaceutical companies in the region working towards improving the quality and efficiency of biologics is also driving the market growth.
The biologics market share is rapidly growing in Europe, owing to its advanced healthcare system and the increasing demand for personalized medicines. Several biopharmaceutical companies in the region are expanding their product portfolios by entering strategic collaborations which is boosting the market growth. In December 2023, AstraZeneca plc, a multinational pharmaceutical and biotechnology company with its headquarters in England, announced its collaboration with an artificial intelligence biologics firm, Absci, by signing an agreement for up to USD 247 million to develop an antibody against cancer.
Global Biologics Market: Competitor Landscape
In July 2023, a Danish-based medical devices company, Coloplast, announced its acquisition of Kerecis, a wound care company in Iceland, for a deal worth USD 1.3 billion. The acquisition is aimed at expanding the company’s wound care portfolio in the biologics sector. Coloplast plans to leverage Kerecis's advanced technology to treat burns and wounds by using fish skin, which is shown to aid wound healing by facilitating cellular ingrowth. This indicates a market trend of rising mergers and acquisitions which is expected to increase the biologics market size in the forecast period._x000D__x000D_
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Global Biologics Market Overview
Biologics include products obtained from living organisms or their certain components. Biologic drugs can be derived from humans, animals, or microorganisms by utilizing biotechnological techniques. It includes a diverse range of therapeutic products such as vaccines, blood components, tissues, genes, and recombinant proteins. Biologics are considered the most advanced therapies, used for treating diseases such as rheumatoid arthritis, and Crohn’s disease, among other autoimmune disorders.
The biologics market demand is driven by the prevalence of chronic diseases, necessitating the need for improved diagnostics and treatment drugs. There is an increased impetus for research and development activities to enhance the productivity of biologics products. Biologics have shown promising results in the treatment of chronic diseases such as rheumatoid arthritis (RA), which poses a lifetime risk of 4% in women and 3% in men. Studies have revealed that biologics can improve joint function in patients with RA, along with reducing drug dependency. Thus, it opens a wide avenue for effective therapeutics, that can fuel the growth of the biologics market.
Rising Investments to Fuel Biologics Market Growth
The increased investment and funding to accelerate the expansion of biologics research and manufacturing facilities is driving the market growth. In October 2023, Syngene International, Biocon's global innovation-focused subsidiary, announced its annual investment plan of USD 100 million in biologics, research, and small molecules. The company also revealed that their biologics division is rapidly expanding and delivering positive results. With the latest investment strategy, the company plans to enhance their manufacturing capabilities along with capacity expansion to align with the rising demand of the biologics market.
Technological Advancements to Develop High-Quality Biologics
Biologics represent cutting-edge medicines with the potential to treat medical conditions with no other treatment available. Biopharmaceutical companies are working towards developing standards and reference materials to improve quality assessment in the biological therapies space, expected to bolster the biologics market share in the forecast period.
In October 2023, American Type Culture Collection (ATCC) and United States Pharmacopeia (USP), two United States-based nonprofit premier global biological materials management and standard organizations, launched a set of 6 products to mitigate the risk involved in the manufacturing of biologics such as vaccines. The joint products marketed by the companies contain pure genomic DNA that can advance quality control of various biotherapeutic products by measuring residual host cell DNA. The development of such reference materials will ensure the quality and safety of biologics and will subsequently help in the market growth.
Strategic Collaborations to Boost Biologics Market Size
To meet the rising demand for biologics, biopharmaceutical companies are entering into strategic collaborations and partnerships to achieve substantial market share. In October 2023, Salipro Biotech AB (a Sweden-based biotechnology company) and Icosagen (a contract research, development, and manufacturing organization headquartered in Estonia) announced their collaboration to accelerate drug discovery programs. The alliance is primarily focused on monoclonal antibody discovery and characterization against challenging membrane proteins. By leveraging the shared resources and expertise, the companies plan to establish a solid foundation for biologic drug development.
Global Biologics Market Segmentation
"Biologics Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Source
- Microbial
- Mammalian
- Monoclonal Antibodies
- Vaccines
- Recombinant Proteins
- Antisense, RNAi & molecular therapy
- Cell Based Therapies
- Tissue Engineering
- Others
- Oncology
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
North America is the leading market in the biologics sector, which can be attributed to the rising prevalence of chronic diseases and growing awareness around advanced technologies such as gene therapy and RNAi therapy. In addition, the presence of leading biopharmaceutical companies in the region working towards improving the quality and efficiency of biologics is also driving the market growth.
The biologics market share is rapidly growing in Europe, owing to its advanced healthcare system and the increasing demand for personalized medicines. Several biopharmaceutical companies in the region are expanding their product portfolios by entering strategic collaborations which is boosting the market growth. In December 2023, AstraZeneca plc, a multinational pharmaceutical and biotechnology company with its headquarters in England, announced its collaboration with an artificial intelligence biologics firm, Absci, by signing an agreement for up to USD 247 million to develop an antibody against cancer.
Global Biologics Market: Competitor Landscape
In July 2023, a Danish-based medical devices company, Coloplast, announced its acquisition of Kerecis, a wound care company in Iceland, for a deal worth USD 1.3 billion. The acquisition is aimed at expanding the company’s wound care portfolio in the biologics sector. Coloplast plans to leverage Kerecis's advanced technology to treat burns and wounds by using fish skin, which is shown to aid wound healing by facilitating cellular ingrowth. This indicates a market trend of rising mergers and acquisitions which is expected to increase the biologics market size in the forecast period._x000D__x000D_
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AbbVie Inc.
- Amgen Inc.
- Lilly
- F. Hoffmann-La Roche AG
- Samsung Biologics
- Sanofi
- Pfizer Inc.
- Merck & Co., Inc.
- Novo Nordisk A/S
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Celltrion Inc.
- BD
- Bayer AG
- AstraZeneca
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Biologics Market Overview
- 3.1 Global Biologics Market Historical Value (2018-2024)
- 3.2 Global Biologics Market Forecast Value (2025-2034)
- 4 Global Biologics Market Landscape*
- 4.1 Global Biologics Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Biologics Product Landscape
- 4.2.1 Analysis by Source
- 4.2.2 Analysis by Product
- 5 Global Biologics Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Biologics Market Segmentation (218-2034)
- 6.1 Global Biologics Market (2018-2034) by Source
- 6.1.1 Market Overview
- 6.1.2 Microbial
- 6.1.3 Mammalian
- 6.2 Global Biologics Market (2018-2034) by Product
- 6.2.1 Market Overview
- 6.2.2 Monoclonal Antibodies
- 6.2.2.1 Human mABs
- 6.2.2.2 Humanized mABs
- 6.2.2.3 Chimeric mABs
- 6.2.2.4 Murine mABs
- 6.2.3 Vaccines
- 6.2.4 Recombinant Proteins
- 6.2.5 Antisense, RNAi & molecular therapy
- 6.2.6 Cell Based Therapies
- 6.2.6.1 Stem Cell Therapy
- 6.2.6.2 CAR-T Cell Therapy
- 6.2.7 Tissue Engineering
- 6.2.8 Others
- 6.3 Global Biologics Market (2018-2034) by Indication
- 6.3.1 Market Overview
- 6.3.2 Oncology
- 6.3.3 Immunological Disorders
- 6.3.4 Cardiovascular Disorders
- 6.3.5 Hematological Disorders
- 6.3.6 Others
- 6.4 Global Biologics Market (2018-2034) by Distribution Channel
- 6.4.1 Hospital Pharmacies
- 6.4.2 Retail Pharmacies
- 6.4.3 Online Pharmacies
- 6.5 Global Biologics Market (2018-2034) by Region
- 6.5.1 Market Overview
- 6.5.2 North America
- 6.5.3 Europe
- 6.5.4 Asia Pacific
- 6.5.5 Latin America
- 6.5.6 Middle East and Africa
- 7 North America Biologics Market (218-2034)
- 7.1 North America Biologics Market (2018-2034) by Source
- 7.1.1 Market Overview
- 7.1.2 Microbial
- 7.1.3 Mammalian
- 7.2 North America Biologics Market (2018-2034) by Product
- 7.2.1 Market Overview
- 7.2.2 Monoclonal Antibodies
- 7.2.2.1 Human Monoclonal Antibodies
- 7.2.2.2 Humanized Monoclonal Antibodies
- 7.2.2.3 Chimeric Monoclonal Antibodies
- 7.2.2.4 Murine Monoclonal Antibodies
- 7.2.3 Vaccines
- 7.2.4 Recombinant Proteins
- 7.2.5 Antisense, RNAi & molecular therapy
- 7.2.6 Cell Based Therapies
- 7.2.6.1 Stem Cell Therapy
- 7.2.6.2 CAR-T Cell Therapy
- 7.2.7 Tissue Engineering
- 7.2.8 Others
- 7.3 North America Biologics Market (2018-2034) by Country
- 7.3.1 United States of America
- 7.3.2 Canada
- 8 Europe Biologics Market (218-2034)
- 8.1 Europe Biologics Market (2018-2034) by Source
- 8.1.1 Market Overview
- 8.1.2 Microbial
- 8.1.3 Mammalian
- 8.2 Europe Biologics Market (2018-2034) by Product
- 8.2.1 Market Overview
- 8.2.2 Monoclonal Antibodies
- 8.2.2.1 Human mABs
- 8.2.2.2 Humanized mABs
- 8.2.2.3 Chimeric mABs
- 8.2.2.4 Murine mABs
- 8.2.3 Vaccines
- 8.2.4 Recombinant Proteins
- 8.2.5 Antisense, RNAi & molecular therapy
- 8.2.6 Cell Based Therapies
- 8.2.6.1 Stem Cell Therapy
- 8.2.6.2 CAR-T Cell Therapy
- 8.2.7 Tissue Engineering
- 8.2.8 Others
- 8.3 Europe Biologics Market (2018-2034) by Country
- 8.3.1 United Kingdom
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Others
- 9 Asia Pacific Biologics Market (218-2034)
- 9.1 Asia Pacific Biologics Market (2018-2034) by Source
- 9.1.1 Market Overview
- 9.1.2 Microbial
- 9.1.3 Mammalian
- 9.2 Asia Pacific Biologics Market (2018-2034) by Product
- 9.2.1 Market Overview
- 9.2.2 Monoclonal Antibodies
- 9.2.2.1 Human mABs
- 9.2.2.2 Humanized mABs
- 9.2.2.3 Chimeric mABs
- 9.2.2.4 Murine mABs
- 9.2.3 Vaccines
- 9.2.4 Recombinant Proteins
- 9.2.5 Antisense, RNAi & molecular therapy
- 9.2.6 Cell Based Therapies
- 9.2.6.1 Stem Cell Therapy
- 9.2.6.2 CAR-T Cell Therapy
- 9.2.7 Tissue Engineering
- 9.2.8 Others
- 9.3 Asia Pacific Biologics Market (2018-2034) by Country
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 Australia
- 9.3.5 ASEAN
- 9.3.6 Others
- 10 Latin America Biologics Market (218-2034)
- 10.1 Latin America Biologics Market (2018-2034) by Source
- 10.1.1 Market Overview
- 10.1.2 Microbial
- 10.1.3 Mammalian
- 10.2 Latin America Biologics Market (2018-2034) by Product
- 10.2.1 Market Overview
- 10.2.2 Monoclonal Antibodies
- 10.2.2.1 Human mABs
- 10.2.2.2 Humanized mABs
- 10.2.2.3 Chimeric mABs
- 10.2.2.4 Murine mABs
- 10.2.3 Vaccines
- 10.2.4 Recombinant Proteins
- 10.2.5 Antisense, RNAi & molecular therapy
- 10.2.6 Cell Based Therapies
- 10.2.6.1 Stem Cell Therapy
- 10.2.6.2 CAR-T Cell Therapy
- 10.2.7 Tissue Engineering
- 10.2.8 Others
- 10.3 Latin America Biologics Market (2018-2034) by Country
- 10.3.1 Brazil
- 10.3.2 Argentina
- 10.3.3 Mexico
- 10.3.4 Others
- 11 Middle East and Africa Biologics Market (218-2034)
- 11.1 Middle East and Africa Biologics Market (2018-2034) by Source
- 11.1.1 Market Overview
- 11.1.2 Microbial
- 11.1.3 Mammalian
- 11.2 Middle East and Africa Biologics Market (2018-2034) by Product
- 11.2.1 Market Overview
- 11.2.2 Monoclonal Antibodies
- 11.2.2.1 Human mABs
- 11.2.2.2 Humanized mABs
- 11.2.2.3 Chimeric mABs
- 11.2.2.4 Murine mABs
- 11.2.3 Vaccines
- 11.2.4 Recombinant Proteins
- 11.2.5 Antisense, RNAi & molecular therapy
- 11.2.6 Cell Based Therapies
- 11.2.6.1 Stem Cell Therapy
- 11.2.6.2 CAR-T Cell Therapy
- 11.2.7 Tissue Engineering
- 11.2.8 Others
- 11.3 Middle East and Africa Biologics Market (2018-2034) by Country
- 11.3.1 Saudi Arabia
- 11.3.2 United Arab Emirates
- 11.3.3 Nigeria
- 11.3.4 South Africa
- 11.3.5 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape (Customisable)
- 17.1 AbbVie Inc.
- 17.1.1 Company Overview
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 Amgen Inc.
- 17.2.1 Company Overview
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Lilly
- 17.3.1 Company Overview
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 F. Hoffmann-La Roche AG
- 17.4.1 Company Overview
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Samsung Biologics
- 17.5.1 Company Overview
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Sanofi
- 17.6.1 Company Overview
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Pfizer Inc.
- 17.7.1 Company Overview
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Merck & Co., Inc.
- 17.8.1 Company Overview
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Novo Nordisk A/S
- 17.9.1 Company Overview
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 Johnson & Johnson Services, Inc.
- 17.10.1 Company Overview
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Bristol-Myers Squibb Company
- 17.11.1 Company Overview
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Celltrion Inc.
- 17.12.1 Company Overview
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 BD
- 17.13.1 Company Overview
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 Bayer AG
- 17.14.1 Company Overview
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisitions
- 17.14.5 Certifications
- 17.15 AstraZeneca
- 17.15.1 Company Overview
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisitions
- 17.15.5 Certifications
- 18 Global Biologics Market - Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
